Abstract
Tuberculosis treatment is shortened to six months by the indispensable addition of pyrazinamide (PZA) to the drug regimen that includes isoniazid and rifampin1,2. PZA is a pro-drug of pyrazinoic acid (POA) (ref. 3), whose target of action has never been identified. Although PZA is active only against Mycobacterium tuberculosis, the PZA analog 5-chloro-pyrazinamide (5-Cl-PZA) displays a broader range of anti-mycobacterial activity4. We have found that the eukaryotic-like fas1 gene5 (encoding fatty acid synthetase I, FASI) from M. avium, M. bovis BCG or M. tuberculosis confers resistance to 5-Cl-PZA when present on multi-copy vectors in M. smegmatis. 5-Cl-PZA and PZA markedly inhibited the activity of M. tuberculosis FASI, the biosynthesis of C16 to C24/C26 fatty acids from acetyl-CoA (ref. 6). Importantly, PZA inhibited FASI in M. tuberculosis in correlation with PZA susceptibility. These results indicate that FASI is a primary target of action for PZA in M. tuberculosis. Further characterization of FASI as a drug target for PZA may allow the development of new drugs to shorten the therapy against M. tuberculosis and may provide more options for treatment against M. bovis, M. avium and drug resistant M. tuberculosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bass Jr, J.B. et al. Treatment of tuberculosis infection in adults and children. Am. J. Respir. Crit. Care. Med. 149, 1359–1374 (1994).
Steele, M.A. & Des Prez, R.M. The role of pyrazinamide in tuberculosis chemotherapy. Chest. 94, 845–850 (1988).
Konno K., Feldmann, F.M. & McDermott, W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95, 461–469 (1967).
Cynamon, M.H., Speirs, R.J. & Welch, J.T. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob. Agents. Chemother. 42, 462–463 (1998).
Fernandes, N.D. & Kolattukudy, P.E. Cloning, sequencing and characterization of a fatty acid synthase –encoding gene from Mycobacterium tuberculosis variant BCG. Gene. 170, 95–99 (1996).
Brindley, D.N., Matsumura, S & Bloch, K. Mycobacterium phlei fatty acid synthetase a bacterial multienzyme complex. Nature 224, 666–669 (1969).
Kushner, S. et al. Experimental chemotherapy of tuberculosis. The synthesis of pyrazinamide and related compounds. J. Am. Chem. Soc. 74, 3617–3621 (1952).
Scorpio, A & Zhang, Y. Mutations in pncA a gene encoding pyrazinamidase/nicotinamidase cause resistance to the antituberculosis drug pyrazinamide in M. tuberculosis. Nature Med. 2, 662–667 (1996).
Scorpio, A. et al. Characterization of the pncA mutations in pyrazinamide–resistant Mycobacterium tuberculosis. Antimicrob. Agents. Chemother. 41, 540–543 (1997).
Good, R.C., Silcox, V.A., Kilborn, J.O & Plikaytis, B.D. Identification and drug susceptibility test results for Mycobacteria species. Clin. Microbiol.. Newslett. 7, 133–136 (1985).
McDermott W. & Tompsett, R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuber. 70, 748–754 (1954).
Zhang, Y., Scorpio, A., Nikaido, H & Sun, Z. Role of Acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 181, 2044–2049 (1999).
Cynamon, M.H. et al. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. J. Med. Chem. 38, 3902–3907 (1995).
Banerjee. A. et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263, 227–230 (1994).
Telenti, A. et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nature Med. 3, 567–570 (1997).
Kolattukudy, P.E., Fernandes, N.D., Azad., A.K., Fitzmaurice, A.M & Sirakova, A.T. Biochemistry and molecular genetics of cell-wall lipid biosynthesis in mycobacteria. Mol. Microbiol. 24, 263–270 (1997).
Cole, S.T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537–544 (1998).
Kikuchi, S., Rainwater, D.L & Kolattukudy, P.E. Purification and characterization of an usually large fatty acid synthase, from Mycobacterium tuberculosis var. bovis BCG. Arch. Biochem. Biophys. 295, 318–326 (1992).
Anderson, R.J. The chemistry of the lipoids of tubercle bacilli. J. Biol. Chem. 135, 327–337 (1929).
Folch, J., Lees, M. & Sloane-Stanley, G.H.S. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226, 497–509 (1957).
Slayden, R. A. et al. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob. Agents. Chemother. 40, 2813–2819 (1996).
Omura, S. Cerulenin. Methods. Enzymol. 72, 520–532 (1981).
Mdluli, K. et al. Inhibition of a Mycobacteria tuberculosis ∄-Ketoacyl ACP synthase by isoniazid. Science 280, 1607–1610 (1998).
Takayama, K., Schonoes, H.K., Armstrong, E.L & Boyle, R.D. Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium Tuberculosis. J. Lipid Res. 16, 308–317 (1975).
Mehta, A., Oeser, A.M., Carlson, M.G. Rapid quantitation of free fatty acids in human plasma by high-performance liquid chromatography. J. Chromatog. B. 719, 9–23 (1998).
Hagen, S.R, Thompson J.D. Analysis of mycolic acids by high- performance liquid chromatography and fluorimetric detection. Implication for the identification of mycobacteria in clinical samples. J. Chromatog. A. 692, 167–172 (1995).
Bloch, K. Fatty acid synthases from Mycobacterium phlei. Methods Enzymol. 35, 84–90 (1975).
Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with Human Immunodeficiency Virus: Principles of therapy and revised recommendations. MMWR. Morb. Mortal. Wkly. Rep. 47 (RR20) 1–51 (1998).
Mitchison, D.A. The action of antituberculosis drugs in short-course chemotherapy of M. tuberculosis. Tubercle 66, 219 (1985).
Grosset, J. The sterilizing value of rifampin and pyrazinamide in experimental short course chemotherapy. Tubercle 59, 287–297 (1978).
McCune, R.M., Jr., Tompsett, R., Mcdermott, W.J. The fate of Mycobacterium tuberculosis in mouse as determined by the microbial enumeration technique. J. Exp. Med. 104, 763–803 (1956).
Salfinger, M., Crowle, A.J. & Reller, L.B. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system. J. Infect. Dis. 162, 201–207. (1990).
Acknowledgements
We thank: A. Kiener of the Biotec division of Lonza for providing 5-hydroxy-pyrazinoic acid, Carlos Vaamonde for M. avium cosmid library, John Chan for critical review of the manuscript, T. Weisbord and R. Lucos for sequence analysis, Ms. J. Nguyen and N. Nakata for help in isolation and processing 5-Cl-PZA resistant mutants. O.Z is a fellow on the Molecular Pathogenesis of Infectious Diseases training grant from the National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zimhony, O., Cox, J., Welch, J. et al. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 6, 1043–1047 (2000). https://doi.org/10.1038/79558
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/79558
This article is cited by
-
Structural insights of the elongation factor EF-Tu complexes in protein translation of Mycobacterium tuberculosis
Communications Biology (2022)
-
The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD
Nature Communications (2020)
-
Mycobacterium tuberculosis ribosomal protein S1 (RpsA) and variants with truncated C-terminal end show absence of interaction with pyrazinoic acid
Scientific Reports (2020)
-
Synthesis, biological evaluation, molecular docking, and ADMET studies of some isoxazole-based amides
Medicinal Chemistry Research (2018)
-
Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA
Scientific Reports (2017)